** Shares of cancer therapy maker Legend Biotech LEGN.O rise 4.2% to $41.25 premarket
** Partner Johnson & Johnson JNJ.N reports Q2 sales of blood cancer cell therapy Carvykti of $439 mln vs consensus estimates of $419 mln
** JNJ says Carvykti increase is driven by continued share gains and capacity expansion
** "We look to continued growth in 2H25, and expect revenue to accelerate given a typically strong back half, especially with additional production likely to come online,"- brokerage RBC Capital Markets
** We like that Carvykti continues to grow at ~19% quarter over quarter, suggesting there is still untapped demand in the myeloma market, which can enable further growth in 2H25 and 2026, brokerage says
** Up to last close, LEGN up 21.7% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。